Skip to Main content Skip to Navigation
New interface
Journal articles

Interfering peptides targeting protein–protein interactions: the next generation of drugs?

Abstract : Protein-protein interactions (PPIs) are well recognized as promising therapeutic targets. Consequently, interfering peptides (IPs) - natural or synthetic peptides capable of interfering with PPIs - are receiving increasing attention. Given their physicochemical characteristics, IPs seem better suited than small molecules to interfere with the large surfaces implicated in PPIs. Progress on peptide administration, stability, biodelivery and safety are also encouraging the interest in peptide drug development. The concept of IPs has been validated for several PPIs, generating great expectations for their therapeutic potential. Here, we describe approaches and methods useful for IPs identification and in silico, physicochemical and biological-based strategies for their design and optimization. Selected promising in-vivo-validated examples are described and advantages, limitations and potential of IPs as therapeutic tools are discussed.
Complete list of metadata
Contributor : Nicolas Wolff Connect in order to contact the contributor
Submitted on : Monday, June 29, 2020 - 3:21:30 PM
Last modification on : Friday, October 7, 2022 - 3:57:03 AM



Heriberto Bruzzoni-Giovanelli, Valérie Alezra, Nicolas Wolff, Chang-Zhi Dong, Pierre Tufféry, et al.. Interfering peptides targeting protein–protein interactions: the next generation of drugs?. Drug Discovery Today Biosilico, 2018, 23 (2), pp.272-285. ⟨10.1016/j.drudis.2017.10.016⟩. ⟨pasteur-02883922⟩



Record views